Loading…
Employees: 57
Size Altimmune (ALT) is a United States Health Care company (Biotechnology) with a market value of $405M, the 2851st largest of 3,117 United States companies the cockpit tracks. Shares closed at $2.08 on 6 Nov 2026.
Performance Over six months the shares fell 32.7%, against -21.1% for the median peer and -1.1% for the United States market (cap-weighted) — 9th lowest of 21 in its peer set.
Growth Revenue grew 55.0% over the last twelve months (peer median +12.2%); the operating margin is -320,725.8% (peer median -7.1%).
Valuation It trades at 3,686.9× enterprise value to sales against a peer median of 4.2× (most expensive of 16).
Capital Return on invested capital runs 49.0 points below its cost of capital (6.3% WACC).
Short interest Short interest is 21.7% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $31,000 | $41,000 | $20,000 | $426,000 | -$68,000 |
| Revenue growth | — | +105% | -95% | — | — |
| Gross profit | -$68,000 | -$71,000 | -$218,000 | -$51,000 | -$568,000 |
| EBITDA | -$99.3M | -$94.4M | -$103M | -$83.0M | -$87.2M |
| Net income | -$91.8M | -$88.1M | -$95.1M | -$88.4M | -$84.7M |
| Free cash flow | -$76.3M | -$67.5M | -$79.8M | -$76.1M | -$62.7M |
| Capital expenditure | $54,000 | $11,000 | $0 | $47,000 | $126,000 |
| Total debt | $36.0M | $35.7M | $1.68M | $671,000 | $1.12M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALT | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -20.0% | -7.5% | 5th lowest of 21 |
| 6-month return | -32.7% | -21.1% | 9th lowest of 21 |
| Distance from 52-week high | -67.7% | -44.7% | 2nd lowest of 21 |
| Revenue growth (TTM) | +55.0% | +12.2% | 6th highest of 17 |
| Operating margin | -320,725.8% | -7.1% | lowest of 17 |
| EV / Sales | 3,686.9× | 4.2× | most expensive of 16 |
| ROIC minus cost of capital | -49.0 pp | -8.1 pp | 4th lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Altimmune ALT | United States | $405M | -33% | +55% | -320,726% | 3,686.9× | n/a | n/a |
| Edding Genor 6998.HK | Hong Kong | $408M | -45% | +1,418% | 26% | 0.9× | -15.8% | +197.3% |
| Prothena PRTA | United States | $409M | -26% | +427% | -110% | 2.4× | n/a | n/a |
| Beijing Kawin Technology Share-Holding 688687.SS | China | $410M | -19% | +3% | 0% | 1.6× | 43.0% | +8.9% |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | 0.7× | n/a | n/a |
| Editas Medicine EDIT | United States | $395M | -17% | +21% | -178% | 5.4× | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 2.5× | -20.2% | n/a |
| Zura Bio ZURA | United States | $394M | -15% | n/a | n/a | n/a | n/a | n/a |
| PureTech Health PRTC.L | United Kingdom | $394M | -8% | -4% | -1,617% | 28.4× | n/a | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 1.8× | 4.1% | +6.5% |
| Onconic Therapeutics 476060.KS | South Korea | $391M | -45% | +179% | 21% | 5.7× | 2.0% | +725.2% |
| Beijing Luzhu Biotechnology 2480.HK | Hong Kong | $390M | -33% | n/a | n/a | n/a | n/a | n/a |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Rznomics 476830.KS | South Korea | $386M | -79% | -72% | -1,440% | 244.5× | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 4.2× | 53.3% | +37.6% |
| Guangdong Vtr Bio-Tech 300381.SZ | China | $384M | -23% | -4% | -4% | 2.7× | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | 10.7× | n/a | n/a |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | 6.4× | n/a | n/a |
| C4 Therapeutics CCCC | United States | $381M | +5% | +2% | -288% | 5.3× | n/a | n/a |
| Contineum Therapeutics CTNM | United States | $381M | -34% | n/a | n/a | n/a | n/a | n/a |
| AgomAb Therapeutics NV ADR AGMB | United States | $376M | -37% | n/a | n/a | n/a | n/a | n/a |